A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

228 participants · First posted Apr 17, 2024

To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

284 participants · First posted Dec 19, 2024

Daratumumab for Patients With Light Chain Amyloidosis

100 participants · First posted Apr 19, 2024

Amivantamab-vmjw(Rybrevant)

lispro

HDV-Lispro

MABPRO, a.s.

Slovakia

ASPIRO PHARMA LIMITED

India

AUSPRO HEALTH PTY LTD

Australia

Subcutaneous Amivantamab Plus Lazertinib Shows 70% 3-Year Survival in EGFR-Mutated NSCLC

PAPILLON Final Analysis: RYBREVANT Plus Chemotherapy Delivers Longest Reported Median Overall Survival in EGFR Exon 20 Insertion NSCLC

Johnson & Johnson's Oncology Pipeline Surge: Firefly Bio Acquisition, Sail Biomedicines CAR-T Deal, and OTTAVA Robotic System FDA Authorization